Navigation Links
KV Pharmaceutical Company Completes New Board with Appointment of Former Johnson & Johnson Executive
Date:11/5/2013

ST. LOUIS, Nov. 5, 2013 /PRNewswire-USNewswire/ -- K-V Pharmaceutical Company ("KV") today announced the appointment of Janet Vergis to its Board of Directors.  Ms. Vergis currently serves as the Executive-In-Residence at Warburg Pincus, LLC.  Previously, she was the CEO of OraPharma, Inc. where she led the company's successful turnaround.  Prior to her role at OraPharma, Ms. Vergis managed a $6 billion portfolio at Johnson & Johnson as President of Janssen Pharmaceuticals, McNeil Pediatrics, and Ortho-McNeil Neurologics.  Ms. Vergis also contributed to a number of Johnson & Johnson companies during her career, serving as a member of company management boards for more than 10 years and holding positions of increasing responsibility in research and development, new product development, sales, and marketing.

"Janet has a proven track record with some of the leading pharmaceutical companies in the world," said Greg Divis, KV CEO.  "Her extensive knowledge and valuable insights will help guide us as our company continues to pursue helping women achieve healthier lives and healthier pregnancies."

"With more than 25 years of pharmaceutical leadership experience and longstanding success growing and developing businesses, Janet will be a tremendous asset to the KV Board and complements the skill sets of our other Board members," said Joseph M. Mahady, Chairman of the KV Board of Directors.

Janet Vergis is the final appointment to KV's new Board of Directors.  The company recently appointed former President of Wyeth Pharmaceuticals, Inc., Joseph Mahady, as its new Board Chair, and two Board members: Gregory Norden, former Senior Vice President and Chief Financial Officer for Wyeth Corporation, and James M. Goldfarb, MD, MBA, Director of Infertility Services of the University Hospitals of Cleveland Health Systems and Clinical Professor of Reproductive Biology at Case Western Reserve University (CWRU) School of Medicine. The recently-announced Directors join Joe McInnis, Managing Director of Greywolf Capital Management LP, Steve Nielson of Susquehanna International Group, and Greg Divis, President and Chief Executive Officer of KV Pharmaceutical on the Board to shape the company's role in advancing women's health as it builds upon its portfolio of FDA-approved medications.

About KV Pharmaceutical
K-V Pharmaceutical Company is a specialty branded pharmaceutical company with a primary focus in the area of women's healthcare. The company is committed to advancing the health of women across the stages of their lives. For further information about K-V Pharmaceutical Company, please visit www.kvph.com.


'/>"/>
SOURCE K-V Pharmaceutical Company
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Report Presents a Framework for Successful New Oncology Product Launches in the Pharmaceutical Sector
2. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
3. Pharmaceutical Industry Service Company Awarded The UKs Most Prestigious Business Accolade in Recognition of Outstanding Achievement in International Trade
4. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
5. Simcere Pharmaceutical Group to Announce First Quarter 2012 Financial Results on Wednesday, May 9, 2012
6. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
7. Thomson Reuters Launches New Mobile Oncology Decision Support Solution for R&D Pharmaceutical Leaders
8. Amgen to Acquire Mustafa Nevzat, a Leading Privately Held Turkish Pharmaceutical Company
9. BioElectronics Survey Indicates a Five-Fold Superior Pain Relief Compared to OTC Pharmaceuticals
10. Icahn Issues Statement Regarding Amylin Pharmaceuticals
11. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... -- --> --> Transparency ... titled "Sports Medicine Devices Market - Global Industry Analysis, Size, ... the report, the global sports medicine devices market is anticipated ... growing from a value of US$6.1 bn in 2012 to ... --> The global sports medicine devices market is fueled ...
(Date:2/11/2016)... , Feb. 11, 2016 PLAD, Inc. ... out 2016 with sales exceeding company targets, are adding ... received their trademark from the United States Patent and ... Clark , Chief Executive Officer of PLAD, Inc.  In ... Pennsylvania with two new customers, ...
(Date:2/11/2016)... , Feb. 11, 2016 Exactus ... company providing high-quality specialty pharmacy care for those ... today it has achieved full Specialty Pharmacy Accreditation ... organization dedicated to promoting health care quality through ... --> The URAC accreditation process ...
Breaking Medicine Technology:
(Date:2/11/2016)... ... 11, 2016 , ... PharmMD CEO Robert Yeager ... focus on contract negotiations, corporate strategy and healthcare data law. Additional responsibilities will ... in data breaches for the Part D Star Rating improvement and Medication Therapy ...
(Date:2/11/2016)... ... February 11, 2016 , ... AccuVein Inc. announces the Infusion ... of Practice, to include vascular visualization as a standard practice. AccuVein ( http://www.accuvein.com ... the market, facilitates adherence to this standard with its easy to use, widely ...
(Date:2/11/2016)... ... February 11, 2016 , ... The annual list showcases the 20 ... DataPoint’s team dedication and commitment to the SharePoint ecosystem. A panel of ... The panel’s goal is to recognize and promote technology entrepreneurship. , The survey ...
(Date:2/11/2016)... ... February 11, 2016 , ... ... and ergoFET force gauges used in physical therapy, occupational therapy and sports medicine ... for resistance cord exercise and therapy, introduces its new microFET Digital Pinch Gauge. ...
(Date:2/11/2016)... , ... February 11, 2016 , ... ... results in significantly higher rates of several common cancer screenings, especially among women. ... better outcomes and survival rates. , The study,“What Does Medicaid Expansion Mean ...
Breaking Medicine News(10 mins):